Fitzsimons Innovation Community is an integrated urban campus where health and life sciences companies of all sizes work on their next big things. Our customized workspace, collaborative campus, and proximity to one of the top health systems and medical schools in the country make our community the perfect place to put down roots and get to work.
MOVE-IN READY LAB SPACE
GROWTH OPPORTUNITIES
It’s not just additional space—it’s fifty sprawling acres of additional space. And it’s primed for ultra-custom, made-to-order facility development.
Fitzsimons Innovation Community and University of Colorado Anschutz Medical Campus working together.
Relationships that help you thrive.
FEATURED:
One of the most exciting times of year for us here at Fitzsimons Innovation Community is when we launch our Annual Innovation Report, and this year is no different. For the fourth year in a row, we are proud to share this report featuring updates, insight, and data about all the things that make our Community special.
Fitzsimons Innovation Community is where innovators come to turn ideas into business.
A regular feature of a Fitzsimons Innovation Community visionary.
Our year in innovation.
Find out what’s happening on campus and across the industry.
An urban mountain lifestyle for work and play.
Everything you need.
Right here.
Read Fitzsimons Innovation Community news, industry highlights, editorials, and innovation updates happening weekly on our campus.
When Israel Villaseñor, Chief Strategy Officer of IMD Path, talks about his company's journey to Colorado, he uses a word that perfectly captures how it all happened: serendipitous. What started as a California-focused molecular diagnostics company has found a true home right here at Fitzsimons Innovation Community. "If it wasn't for networking and having connections, we would have never known about Fitzsimons," Villaseñor reflects. "We would have probably ended up just locking ourselves into California and not thinking about Colorado."
Colorado Real Estate Journal's latest Health Care and Life Sciences Quarterly features an article from Dr. Terry Fry, Executive Director of the Gates Institute at University of Colorado Anschutz, about how the proximity between academia, biomanufacturing, and industry collaboration at Fitzsimons accelerates the development of life-changing cell and gene therapies.
Precision health and medicine giant Verily will be partnering with CU Anschutz and UCHealth to create an AI enabled ecosystem entailing research ready biomedical pipelines and datasets. In addition, the partnership is aiming to build curated AI models across a variety of specific therapeutic and drug areas, such as oncology, musculoskeletal and transplant medicine, to name a few. All of this work will be done using CU Anschutz’s vast research datasets via Verily Workbench, one of the company’s flagship products.
RheumaGen, Inc. and SiVEC Biotechnologies, Inc. today announced a licensing and joint development agreement for a breakthrough class of gene-editing therapies designed to cure autoimmune diseases. The partnership will utilize SiVEC's BactPac™ drug delivery platform to streamline manufacturing and increase scalability of RheumaGen's new class of human leukocyte antigen (HLA) gene-editing therapies for common autoimmune diseases; importantly, the partnership also establishes an in vivo program that will be co-developed by the companies.
EnteroTrack LLC announced that the Centers for Medicare & Medicaid Services (CMS) is paying for the company’s Esophageal String Test® (EST), marking a major milestone in access for patients living with eosinophilic esophagitis (EoE), a chronic inflammatory condition of the esophagus. The decision means that Medicare beneficiaries can now receive coverage for the EST, which provides a non-endoscopic, minimally invasive method to monitor esophageal inflammation. The test enables clinicians to track disease activity without the need for repeated sedated endoscopies, which are costly, burdensome, and carry procedural risks.
As you know from all the buzz, this year marks a milestone for Fitzsimons Innovation Community—25 years since the opening of our first labs in Bioscience 1 in 2000. In all of those 25 years, and even before that, one of the biggest challenges facing Colorado’s life sciences ecosystem has been clear: access to capital. With major investment firms concentrated on the coasts, Colorado companies often found themselves out of sight and out of mind, forced to travel across the country to meet with investors who might not understand the unique strengths of our state’s innovation ecosystem. That’s changing. Enter Stout Street Capital and their newly announced Unmet Frontier Fund, backed by the State of Colorado through the Venture Capital Authority.
Change Please was named one of Instawork’s Community Partner of the Year winners for 2025. The Community Partner Awards recognized businesses prioritizing hiring from underserved local communities. With a Denver area location at Fitzsimons Innovation Community, the Change Please mission is to tackle homelessness through employment, training, and holistic support is transforming lives.
Fitzsimons Innovation Community
